Genmab — Marts 2017
-
CRISPR-selskab vil rejse 622 mio kr
Et af de førende selskaber inden for brugen af den revolutionerende genredigeringsteknik CRISPR vil sælge ud af sine aktier, hvilket kan indbringe selskabet næsten 622 mio. kr. - eller mere hvis en overtegningsret udnyttes.
(medwatch.dk)
-
-
-
in NICE website as previous link didnt work
https://www.nice.org.uk/guidance/indevelopment/gid-ta10076/documents -
"
This is not the only appraisal in the pipeline for daratumumab. NICE is also currently considering a separate appraisal looking at daratumumab in combination with established myeloma drugs – lenalidomide (Revlimid
) or bortezomib (Velcade) for relapsed and/or refractory myeloma." https://www.myeloma.org.uk/blog/news/nice-issue-draft-no-on-daratumumab-monotherapy/#1489748505348-01faf5c2-9725
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind